| 46(2)(a) | Details of business | The Company is primarily engaged in the business of research, manufacture, marketing and sale of pharmaceutical formulations in the international markets. |
| 46(2)(aa) | Memorandum of Association and Articles of Association | moa-aoa.pdf |
| 46(2)(ab) | Brief profile of board of directors including directorship and full-time positions in body corporates |
Pharmaceutical Formulation Manufacturers in Mumbai, India - Marksans Pharma Microsoft Word - List of Directors and their directorship |
| 46(2)(b) | Terms and conditions of appointment of independent directors | https://www.marksanspharma.com/independent-directors.html |
| 46(2)(c) | Composition of various committees of board of directors | Pharmaceutical Formulation Manufacturers in Mumbai, India - Marksans Pharma |
| 46(2)(d) | Code of conduct of board of directors and senior management personnel | https://www.marksanspharma.com/pdf/Code-of-Conduct.pdf |
| 46(2)(e) | Details of establishment of vigil mechanism / Whistle Blower policy | https://www.marksanspharma.com/pdf/whistle-blower-policy.pdf |
| 46(2)(f) | Criteria of making payments to non-executive directors | https://www.marksanspharma.com/pdf/nomination-and-remuneration-policy.pdf |
| 46(2)(g) | Policy on dealing with related party transactions | Policy-on-materiality-of-related-party-transactions-and-on-dealing-with-related-party-transactions.pdf |
| 46(2)(h) | Policy for determining ‘material’ subsidiaries | policy-on-material-subsidiary.pdf |
| 46(2)(i) | Details of familiarization programmes imparted to independent directors | https://www.marksanspharma.com/independent-directors.html |
| 46(2)(j) | Email address for grievance redressal and other relevant details |
https://www.marksanspharma.com/contact-us.html https://www.marksanspharma.com/investor-contact.html |
| 46(2)(k) | Contact information of designated officials responsible for investor grievance | https://www.marksanspharma.com/investor-contact.html |
| 46(2)(l) | Financial information | |
| (i) Notice of meeting of the board of directors | https://www.marksanspharma.com/corporate-announcements.html | |
| (ii) Financial results | https://www.marksanspharma.com/quarterly-results.html | |
| (iii) Complete copy of the annual report | https://www.marksanspharma.com/annual-reports.html | |
| 46(2)(m) | Shareholding pattern | https://www.marksanspharma.com/shareholding-pattern.html |
| 46(2)(n) | Details of agreements entered into with the media companies and/or their associates | NA |
| 46(2)(o) | Schedule of analyst or institutional investor meet Presentations prepared by the listed entity for analysts or institutional investors meet, post earnings or quarterly calls prior to beginning of such events |
https://www.marksanspharma.com/earnings-call-transcripts.html https://www.marksanspharma.com/investors-presentation.html https://www.marksanspharma.com/earnings-call-transcripts.html |
| 46(2)(oa) | Audio recordings, video recordings, if any, and transcripts of post earnings or quarterly calls, by whatever name called, conducted physically or through digital means | https://www.marksanspharma.com/earnings-call-transcripts.html |
| 46(2)(p) | New name and the old name of the listed entity | NA |
| 46(2)(q) | Advertisements as per Regulation 47 (1) | https://www.marksanspharma.com/newspaper-advertisement.html |
| 46(2)(r) | Credit rating or revision in credit rating obtained | https://www.marksanspharma.com/corporate-announcements.html |
| 46(2)(s) | Separate audited financial statements of each subsidiary of the listed entity in respect of a relevant financial year | https://www.marksanspharma.com/subsidiary-accounts.html |
| 46(2)(t) | Secretarial Compliance Report | https://www.marksanspharma.com/others-disclosures.html |
| 46(2)(u) | Materiality Policy as per Regulation 30 (4) | policy-for-determination-of-materiality-of-events-or-information-and-disclosures.pdf |
| 46(2)(v) | Disclosure of contact details of KMP who are authorized for the purpose of determining materiality as required under regulation 30(5) | policy-for-determination-of-materiality-of-events-or-information-and-disclosures.pdf |
| 46(2)(w) | Disclosures under regulation 30(8) | https://www.marksanspharma.com/corporate-announcements.html |
| 46(2)(x) | Statements of deviation(s) or variations(s) as specified in regulation 32 | https://www.marksanspharma.com/corporate-announcements.html |
| 46(2)(y) | Dividend Distribution Policy | https://www.marksanspharma.com/pdf/dividend-distribution-policy.pdf |
| 46(2)(z) | Annual return as per Section 92 of Companies Act, 2013 | https://www.marksanspharma.com/annual-reports.html |
| 46(2)(za) | Employee Benefit scheme documents (SEBI SBEB Regulations 2021) | https://www.marksanspharma.com/pdf/grant-of-stock-options.pdf |
